Goutam Chakraborty
Overview
Explore the profile of Goutam Chakraborty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chakraborty G, Wang W, Chakraborty B, Tai S, Lo Y
IEEE J Biomed Health Inform
. 2022 Oct;
27(1):65-74.
PMID: 36251916
Hepatocellular carcinoma (HCC) is one of the most critical health problems in the world. For proper treatment, it is important to identify the grade of cancer morbidity from HCC biopsy...
12.
Gadly T, Patro B, Chakraborty G
Colloids Surf B Biointerfaces
. 2022 Sep;
220:112865.
PMID: 36174489
Herein we report fluorogenic derivative of gemcitabine (GEM-DNS), synthesized from gemcitabine hydrochloride and dansyl chloride in a single step. Owing to its large stoke shift of ∼200 nm and intriguing...
13.
Chakraborty G
Int J Biol Macromol
. 2022 Sep;
221:1527-1535.
PMID: 36122782
Development of simple, fast and non-destructive technique such as fluorescence based method for the quantification of milk allergens in various dairy products is a highly rewarding task. In this contribution,...
14.
Yoshikawa Y, Stopsack K, Wang X, Chen Y, Mazzu Y, Burton F, et al.
Mol Oncol
. 2022 Sep;
16(22):3994-4010.
PMID: 36087093
Loss of the histone demethylase KDM5D (lysine-specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. We aimed to...
15.
Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack K, Kreitzer C, et al.
Clin Cancer Res
. 2022 Jun;
28(16):3603-3617.
PMID: 35670774
Purpose: Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate...
16.
Nitin B, Sandilya P, Chakraborty G
Environ Sci Pollut Res Int
. 2022 Apr;
30(10):24963-24974.
PMID: 35459996
Fuel cells are gaining popularity because of their efficient energy production without causing environmental pollution. Recently, DRDO has developed a fuel cell-based air-independent propulsion (AIP) system. In this system, the...
17.
Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, et al.
Cell Rep
. 2022 Apr;
39(1):110595.
PMID: 35385726
Bioinformatic analysis of 94 patient-derived xenografts (PDXs), cell lines, and organoids (PCOs) identifies three intrinsic transcriptional subtypes of metastatic castration-resistant prostate cancer: androgen receptor (AR) pathway + prostate cancer (PC)...
18.
Korsen J, Kalidindi T, Khitrov S, Samuels Z, Chakraborty G, Gutierrez J, et al.
J Nucl Med
. 2022 Jan;
63(9):1401-1407.
PMID: 35058323
Treatment-induced neuroendocrine prostate cancer (NEPC) is a lethal subtype of castration-resistant prostate cancer. Using the Zr-labeled delta-like ligand 3 (DLL3) targeting antibody SC16 (Zr-desferrioxamine [DFO]-SC16), we have developed a PET...
19.
Gadly T, Chakraborty G, Tyagi M, Patro B, Dutta B, Potnis A, et al.
Sci Rep
. 2021 Dec;
11(1):24341.
PMID: 34934094
Cellular temperature and pH govern many cellular physiologies, especially of cancer cells. Besides, attaining higher cellular temperature plays key role in therapeutic efficacy of hyperthermia treatment of cancer. This requires...
20.
Mazzu Y, Liao Y, Nandakumar S, Jehane L, Koche R, Rajanala S, et al.
Oncogene
. 2021 Nov;
41(5):671-682.
PMID: 34802033
Chromosome 8q gain is associated with poor clinical outcomes in prostate cancer, but the underlying biological mechanisms remain to be clarified. CSN5, a putative androgen receptor (AR) partner that is...